Featured Research

from universities, journals, and other organizations

Common breast cancer subtype may benefit from personalized treatment approach

Date:
April 4, 2014
Source:
University of Pittsburgh Schools of the Health Sciences
Summary:
The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to new research. Invasive lobular carcinoma, characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers which indicate drug therapies may provide benefits beyond those typically prescribed for the more common invasive ductal carcinoma.

The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by scientists at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.

Invasive lobular carcinoma, characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers which indicate drug therapies may provide benefits beyond those typically prescribed for the more common invasive ductal carcinoma. The results recently were published in Cancer Research and will be expanded upon on Tuesday at the American Association for Cancer Research (AACR) Annual Meeting 2014.

Patients with invasive lobular carcinoma typically are treated through surgical removal of the cancer, followed by chemotherapy or hormone therapy or both, usually with the estrogen-mimicking drug tamoxifen or estrogen-lowering aromatase inhibitors, the same as patients with invasive ductal carcinoma.

"However, recent analyses suggest that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen than patients with ductal carcinoma," said lead author Matthew Sikora, Ph.D., postdoctoral associate at UPCI, and recipient of this year's AACR-Susan G. Komen Scholar-in-Training Award for this research. "Our study, the largest of its kind, indicates an issue with the estrogen receptors inside lobular carcinoma cells and points to potential targets for drug therapy in future clinical trials, which we are developing."

Early studies in developing these potential targets are the topic of Dr. Sikora's AACR presentation, with a focus on a unique signaling pathway regulated by estrogen specifically in lobular carcinoma cells.

Additional researchers on this study include Steffi Oesterreich, Ph.D., and Amir Bahreini, B.S., both of UPCI.

This research was supported by the Breast Cancer Research Foundation, Department of Defense Breast Cancer Research Program and Pennsylvania Department of Health.


Story Source:

The above story is based on materials provided by University of Pittsburgh Schools of the Health Sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. J. Sikora, K. L. Cooper, A. Bahreini, S. Luthra, G. Wang, U. R. Chandran, N. E. Davidson, D. J. Dabbs, A. L. Welm, S. Oesterreich. Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response. Cancer Research, 2014; 74 (5): 1463 DOI: 10.1158/0008-5472.CAN-13-2779

Cite This Page:

University of Pittsburgh Schools of the Health Sciences. "Common breast cancer subtype may benefit from personalized treatment approach." ScienceDaily. ScienceDaily, 4 April 2014. <www.sciencedaily.com/releases/2014/04/140404140209.htm>.
University of Pittsburgh Schools of the Health Sciences. (2014, April 4). Common breast cancer subtype may benefit from personalized treatment approach. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2014/04/140404140209.htm
University of Pittsburgh Schools of the Health Sciences. "Common breast cancer subtype may benefit from personalized treatment approach." ScienceDaily. www.sciencedaily.com/releases/2014/04/140404140209.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Cases Keep Coming for Monrovia's Island Hospital

Ebola Cases Keep Coming for Monrovia's Island Hospital

AFP (Oct. 1, 2014) A look inside Monrovia's Island Hospital, a key treatment centre in the fight against Ebola in Liberia's capital city. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Ebola Puts Stress on Liberian Health Workers

Ebola Puts Stress on Liberian Health Workers

AP (Oct. 1, 2014) The Ebola outbreak is putting stress on first responders in Liberia. Ambulance drivers say they are struggling with chronic shortages of safety equipment and patients who don't want to go to the hospital. (Oct. 1) Video provided by AP
Powered by NewsLook.com
Doctors Reassure Public Ebola Patient Won't Cause Outbreak

Doctors Reassure Public Ebola Patient Won't Cause Outbreak

Newsy (Sep. 30, 2014) After the announcement that the first U.S. patient had been diagnosed with Ebola, doctors were quick to say a U.S. outbreak is highly unlikely. Video provided by Newsy
Powered by NewsLook.com
TX Hospital Confirms Patient Admitted With Ebola

TX Hospital Confirms Patient Admitted With Ebola

AP (Sep. 30, 2014) Medical officials from Texas Health Presbyterian Hospital confirm they are treating a patient with the Ebola virus, the first case found in the US. (Sept. 30 Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins